Overview Financials News + Filings Key Docs Ownership Insiders
|
|
Centessa Pharmaceuticals plc
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 8-K | 10-Q |
| Revenues | | | 100.0% | 100.0% | | |
| Cost of goods sold | | | 219.5% | 307.5% | | |
| Gross profit | | | -119.5% | -207.5% | | |
| Research and development | | | 294.2% | 286.2% | | |
| General and administrative | | | 138.0% | 183.0% | | |
| EBITDA | | | -551.6% | -676.6% | | |
| Depreciation | | | 0.2% | 0.1% | | |
| EBIT | | | -551.7% | -676.7% | | |
| Pre-tax income | | | -556.0% | -696.4% | | |
| Income taxes | | | 0.4% | 0.7% | | |
| Net income | | | -556.4% | -697.1% | | |
|